EGFR and non-small cell lung carcinoma: In patients with NSCLC harboring EGFR mutations, EGFR tyrosine kinase inhibitors (TKIs) exhibit some therapeutic efficacy against BM, however they show limited intracranial progression-free survival (iPFS) of 8 to 10 months [10, 11].